NASDAQ:XOMAP XOMA (XOMAP) Stock Price, News & Analysis $25.76 -0.02 (-0.06%) As of 08/15/2025 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About XOMA Stock (NASDAQ:XOMAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA alerts:Sign Up Key Stats Today's Range$25.65▼$25.6550-Day Range$25.44▼$25.9852-Week Range$24.96▼$26.51Volume223 shsAverage Volume1,544 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.39%Price TargetN/AConsensus RatingN/A Company Overview XOMA Corporation (NASDAQ:XOMAP) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and delivering therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. The company leverages its proprietary protein engineering and antibody discovery platforms to create novel biologic candidates designed to modulate key immune pathways. XOMA’s research focuses on targets implicated in conditions such as systemic lupus erythematosus, rheumatoid arthritis and other chronic inflammatory disorders. XOMA’s pipeline includes multiple antibody candidates at various stages of development, ranging from lead optimization to early clinical trials. The company employs structure‐guided design and high‐throughput screening to enhance the specificity and potency of its product candidates. XOMA also pursues strategic partnerships to co‐develop assets and expand its reach into new therapeutic areas, collaborating with academic institutions and industry leaders to accelerate progress from preclinical discovery to human studies. Founded in 1981 and headquartered in Berkeley, California, XOMA has driven innovation in protein therapeutics for more than three decades. The company operates research facilities in the San Francisco Bay Area and maintains relationships with contract development and manufacturing organizations worldwide. Under the leadership of President and Chief Executive Officer Paul Rubin, XOMA continues to build on its legacy of antibody discovery, with a focus on bringing first‐in‐class and best‐in‐class therapies to patients in need of novel treatments for immune‐mediated diseases.AI Generated. May Contain Errors. Read More Receive XOMAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMAP Stock News HeadlinesXOMA Co. (NASDAQ:XOMAP) Short Interest UpdateAugust 17 at 2:59 AM | americanbankingnews.comLAVA Therapeutics N.V.: LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth. | Paradigm Press (Ad)XOMA-Backed XenoTherapeutics to Acquire Essa PharmaJuly 14, 2025 | marketwatch.comXOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right - NasdaqJune 29, 2025 | nasdaq.comResults: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 16, 2025 | finance.yahoo.comBenchmark Initiates Coverage of XOMA Royalty (XOMA) with Buy RecommendationApril 17, 2025 | msn.comTrimble, Xoma announce new collaborationMarch 11, 2025 | markets.businessinsider.comSee More Headlines XOMAP Stock Analysis - Frequently Asked Questions How have XOMAP shares performed this year? XOMA's stock was trading at $25.88 at the beginning of the year. Since then, XOMAP shares have decreased by 0.5% and is now trading at $25.7550. How do I buy shares of XOMA? Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 7/15 Dividend7/03/2025Ex-Dividend for 7/15 Dividend7/03/2025Dividend Payable7/15/2025Today8/17/2025Next Earnings (Estimated)11/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XOMAP CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$12.77 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:XOMAP) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.